Global Palonosetron Market Size By Type (Injection 0.25 mg/5 mL, Injection 20 mcg/kg (max 1.5 mg)), By Application (Adults, Children), By Region, And Segment Forecasts, 2023 to 2032

The Global Palonosetron Market was valued at USD 1.1 billion in 2023 and is expected to reach USD 1.85 billion by 2031, growing at a CAGR of 6.6% during the forecast period from 2023 to 2031. Palonosetron, a second-generation 5-HT3 receptor antagonist, is primarily used to prevent chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). The increasing prevalence of cancer globally, growing use of chemotherapy, and enhanced focus on improving patient quality of life are key factors driving market growth.

Palonosetron’s longer half-life and superior receptor-binding affinity compared to first-generation drugs have led to its widespread adoption in oncology care settings. Additionally, favorable safety profiles and regulatory approvals in major markets support the drug’s ongoing integration into standard treatment protocols.

Drivers:

1. Rising Global Cancer Burden:

The increasing number of cancer cases worldwide has intensified the use of chemotherapy treatments, which in turn is boosting the demand for effective antiemetics such as palonosetron. It is especially favored due to its extended duration of action and reduced dosing frequency.

2. Advancement in Oncology Supportive Care:

Supportive care in oncology is becoming increasingly prioritized. Palonosetron’s inclusion in multiple clinical guidelines and protocols as a first-line therapy has bolstered its market position.

3. Growing Awareness and Early Diagnosis:

The surge in cancer awareness campaigns and enhanced access to diagnostics are enabling earlier and more frequent use of chemotherapy, driving palonosetron demand.

Restraints:

1. Availability of Generic Substitutes:

The expiration of patents and market entry of generic palonosetron formulations are exerting downward pricing pressures, limiting revenue potential for original manufacturers.

2. High Cost of Branded Drugs:

In several regions, particularly in low-income economies, the high cost of branded palonosetron compared to generics can restrict patient access and market penetration.

Opportunity:

1. Expansion in Emerging Markets:

Emerging economies, particularly in Asia-Pacific and Latin America, are witnessing improved access to cancer care. Expansion of healthcare infrastructure in these regions presents a significant opportunity for market players.

2. Increasing Use in Postoperative Settings:

While palonosetron is well-established in chemotherapy care, its growing use for managing postoperative nausea and vomiting offers a new avenue for market expansion.

Market by System Type Insights:

Based on formulation, the injectable segment held the largest market share in 2023, as most palonosetron products are administered intravenously in hospital or clinical settings. However, the oral capsule segment is expected to register notable growth during the forecast period, driven by increasing preference for at-home care and convenience in administration.

Market by End-use Insights:

The hospital pharmacies segment accounted for the largest revenue share in 2023 due to the high volume of chemotherapy procedures conducted in inpatient settings. The retail pharmacy segment, however, is projected to witness strong growth, supported by expanding outpatient oncology care and improved access to oral formulations.

Market by Regional Insights:

North America dominated the global palonosetron market in 2023, driven by a high cancer burden, strong healthcare infrastructure, and early adoption of advanced antiemetic therapies. Asia-Pacific is expected to witness the fastest growth during the forecast period, attributed to a rising number of cancer cases, increasing healthcare spending, and expanding pharmaceutical distribution networks.

Competitive Scenario:

Key players in the global palonosetron market include:

Helsinn Healthcare SA

Dr. Reddy’s Laboratories

Aurobindo Pharma

Fresenius Kabi

Teva Pharmaceutical Industries Ltd.

Sandoz (Novartis AG)

Cipla Limited

Sun Pharmaceutical Industries Ltd.

These companies are actively engaged in R&D, launching generic versions, and expanding their global footprint through strategic collaborations and regulatory approvals.

Scope of Work – Global Palonosetron Market

Report Metric Details

Market Size (2023) USD 1.1 Billion

Projected Market Size (2031) USD 1.85 Billion

CAGR (2023–2031) 6.6%

Market Segments By Formulation (Injectable, Oral), By End-use (Hospital Pharmacies, Retail Pharmacies)

Growth Drivers Rising cancer incidence, preference for long-acting antiemetics, growth in outpatient chemotherapy centers

Opportunities Emerging markets, rising demand in postoperative care

Key Market Developments:

2023: Dr. Reddy’s Laboratories launched its generic palonosetron hydrochloride injection in the U.S. market, expanding its oncology supportive care portfolio.

2024: Cipla received regulatory approval for oral palonosetron capsules in several African and Southeast Asian countries, increasing its market penetration.

2025: Helsinn partnered with a digital health platform to integrate antiemetic therapy management in outpatient chemotherapy settings, improving patient adherence and outcomes.

FAQs:

1) What is the current market size of the Global Palonosetron Market?

The market was valued at USD 1.1 billion in 2023.

2) What is the major growth driver of the Global Palonosetron Market?

The key growth driver is the rising global cancer burden and increasing use of chemotherapy.

3) Which is the largest region during the forecast period in the Global Palonosetron Market?

North America held the largest market share in 2023, while Asia-Pacific is projected to witness the highest growth.

4) Which segment accounted for the largest market share in the Global Palonosetron Market?

The injectable formulation segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Palonosetron Market?

Major players include Helsinn Healthcare, Dr. Reddy’s, Teva, Aurobindo Pharma, and Cipla.